Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Abstract: A respirator comprising: an air supply unit arranged to deliver air at its output.

Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein RI, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Abstract: The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

Abstract: The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an ?-substituent, either alone or in combination with one or more additional therapeutic agents.

Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein RI, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Abstract: In embodiments of wearable device heart monitor systems, a wearable device has electrical contacts integrated in a housing base of the wearable device as electrodes designed to contact skin of a user while wearing the wearable device. A housing bezel of the wearable device designed as an additional point of contact on the wearable device. The wearable device includes an electromyography (EMG) system to receive electrical signals from at least two of the electrodes and detect muscular movement of the user. Further, the wearable device includes an electrocardiogram (ECG) system to receive and combine the electrical signals from the electrodes when the user touch contacts the housing bezel while wearing the wearable device to complete an ECG loop between the electrodes and the housing bezel for a heart rate reading of the user.

Abstract: Methods are disclosed to reduce apolipoprotein C-III (apoC-III) mRNA or protein in a subject in need thereof, comprising administering a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen.

Abstract: In embodiments of wearable device heart monitor systems, a wearable device has electrical contacts integrated in a housing base of the wearable device as electrodes designed to contact skin of a user while wearing the wearable device. A housing bezel of the wearable device designed as an additional point of contact on the wearable device. The wearable device includes an electromyography (EMG) system to receive electrical signals from at least two of the electrodes and detect muscular movement of the user. Further, the wearable device includes an electrocardiogram (ECG) system to receive and combine the electrical signals from the electrodes when the user touch contacts the housing bezel while wearing the wearable device to complete an ECG loop between the electrodes and the housing bezel for a heart rate reading of the user.

Abstract: In embodiments of wearable device heart monitor systems, a wearable device has electrical contacts integrated in a housing base of the wearable device as electrodes designed to contact skin of a user while wearing the wearable device. A housing bezel of the wearable device designed as an additional point of contact on the wearable device. The wearable device includes an electromyography (EMG) system to receive electrical signals from at least two of the electrodes and detect muscular movement of the user. Further, the wearable device includes an electrocardiogram (ECG) system to receive and combine the electrical signals from the electrodes when the user touch contacts the housing bezel while wearing the wearable device to complete an ECG loop between the electrodes and the housing bezel for a heart rate reading of the user.

Abstract: The invention relates to the generation of electricity from flowing fluid and in the preferred embodiment to a horizontal axis turbine and generator assembly. The present invention is applicable to water turbines and the invention is described in relation to this application. It is however to be appreciated that it is applicable to wind turbines.

Abstract: The combination of a figurine toy and a smartphone-type device, along with display-controlling software apps, the figurine toy having a receptacle, receiving pocket or mating area adapted and structured to temporarily receive and retain the smartphone-type device such that the visual display of the smartphone-type device presents animated facial features for the figurine toy, the smartphone-type device covering the static facial features of the figurine toy when received by the figurine toy.

Abstract: An electrical connector assembly for a cable having a plurality of insulated conductors comprises a body having a respective recess for receiving a terminating pin each of the conductors. A respective spigot sealingly engages within each of the recesses and has a passage for receiving an associated one of the terminating pins. Furthermore a seal is associated with each of the spigots for sealing the spigot relative to the associated terminating pin. The provision of a separate spigot for each of the conductors and for sealing engagement within a respective recess in the body enables the spigots to be sealingly fitted to the conductors prior to each spigot being introduced into its recess and sealingly engaged therein. This provides improved insulation of the conductor and increased creepage distance between the mating electrical parts and the outer surface of the housing of the assembly.

Abstract: An electrical connector assembly for a cable having a plurality of insulated conductors comprises a body having a respective recess for receiving a terminating pin each of the conductors. A respective spigot sealingly engages within each of the recesses and has a passage for receiving an associated one of the terminating pins. Furthermore a seal is associated with each of the spigots for sealing the spigot relative to the associated terminating pin. The provision of a separate spigot for each of the conductors and for sealing engagement within a respective recess in the body enables the spigots to be sealingly fitted to the conductors prior to each spigot being introduced into its recess and sealingly engaged therein. This provides improved insulation of the conductor and increased creepage distance between the mating electrical parts and the outer surface of the housing of the assembly.